China On 26 August 2019, the Chinese legislature, the National People’s Congress (NPC), passed the new Drug Administration Law (DAL), which came into effect on 1 December 2019 and represents one of the most important milestones for the Chinese healthcare industry. This is only the second systematic and structural major revision…

USA Eurasia Group’s Aditya Bhattacharji examines the stalling of healthcare reforms in the US and what changes to US healthcare it is realistic to expect.   Pharma is unlikely to be frog-marched by sweeping federal initiatives, but more incremental changes are likely With anti-pharma sentiment raging at the end of 2018,…

Opinion Nigel Hughes of the European Health Data & Evidence Network (EHDEN) outlines EHDEN’s scope and purpose and highlights why greater collaboration on real-world data (RWD) will be crucial to ensuring better global health outcomes.    Ultimately, EHDEN is striving to ensure 21st century research can be conducted with 21st century…

Top PharmaBoardroom featured a wide range of developments in the life sciences industry in 2019, including a growing focus on China and the Asia Pacific region, which shows no signs of slowing down. Furthermore, along with our contributors, we highlighted developments and forecasts in the rare disease and orphan drug space…

Romania PharmaBoardroom takes a look at the careers of five pharma executives who we spoke to as Romania country managers back in 2015. At the end of 2019, all of them had taken on new responsibilities in different regions.    Gabor Stanislav, Amgen     In Romania, healthcare is commonly considered…

India Biocon, the first Indian company to have a biosimilar drug approved in the US, is taking another step forward with a new manufacturing facility and an expansion into the Australia and New Zealand markets.   We see ourselves as a company that has great capabilities and is investing big time…

Report PharmaBoardroom had the opportunity to sit down with over six hundred key stakeholders in the life sciences industry across fifteen different countries in 2019. The culmination of time spent in these countries and the insights gained from the interviews we conducted resulted in the publishing of thirteen country reports. Here…

Top 5 In 2019 PharmaBoardroom had the exclusive opportunity to speak with executives that are heading up some of European pharma’s top companies. These stakeholders provided insights into their visions and strategies for success and how they are embracing innovation as they forge ahead.      David Loew, Executive Vice President, Sanofi…

Opinion 2019 was a year of innovation and disruption in the life sciences industry. From artificial intelligence to cell and gene therapy, and from generics and biosimilars to geopolitics and healthcare reform, PharmaBoardroom is proud to have collaborated with industry thought leaders to publish their insights on the year’s top trends…

Canada Pamela Fralick of Innovative Medicines Canada (IMC) advocates for a collaborative multi-stakeholder approach to better tackle rare diseases in Canada.   Especially in smaller provinces, it’s virtually impossible to predictably manage the affordability and accessibility of drugs necessary to treat rare disease Around the world, rare diseases are becoming easier…

Europe The EFPIA’s Nathalie Moll outlines the case for a new EU-wide industrial strategy with biopharmaceuticals at its heart.   The pharmaceutical industry is an area of strategic economic and social value where the EU is a global player   Europe has a history as a world leader in medical innovation,…

China Cancer is one of the world’s leading causes of death and in China, the globe’s most populous country, it is an ever-increasing concern. In 2018, there were approximately 4.3 million new cases of cancer in China, and this number is expected to increase to 6.7 million by 2040. Below, we…